Press Release Title Background

GMP Biologics Market to Grow at a CAGR of 16.2% during 2025 to 2035; Driven by Increasing Demand for Biologics and Expansion of Biopharmaceutical Manufacturing

Report Details:
15 Companies Covered
128 Pages

GMP Biologics Market Highlights


GMP Biologics Market Size was estimated at 67.78 USD Billion in 2024. The GMP Biologics industry is projected to grow from 78.76 USD Billion in 2025 to 353.48 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 16.2% during the forecast period 2025 - 2035


The rising need for bio-Pharmaceuticals which include medicinal proteins, vaccines, and monoclonal antibodies, is one of the main factors. Because biologics offer targeted and effective treatments for a variety of illnesses, there is a growing need for GMP-compliant biological products manufacturing. Cell culture, extraction, and formulation are only a few of the many difficult and complex steps involved in the creation of biologics. The intricacy of these processes can lead to issues with scalability, efficiency, and process optimization that can affect the overall cost-effectiveness of GMP production.


Key Players


MRFR recognizes the following companies as the key players in the global GMP Biologics market—Creative Diagnostics, Fisher Bioservices(Thermo Fisher Scientific),  Polpharma Biologics, Intertek, HemaCare, AGC, AstraZeneca plc, Merck KGaA, Sanofi, GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc.,  Novartis AG, Eli Lilly and Company, Samsung Biologics Co. Ltd., WuXi AppTec.


Segment Analysis


The global GMP Biologics market has been segmented based type, and application.


Regional Analysis


The global GMP Biologics market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe GMP Biologics market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The GMP Biologics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World GMP Biologics market comprises of Middle East, Africa, and Latin America.


The largest market share for GMP Biologics was maintained by the North American regional sector. The biopharmaceutical business is well-established and thriving in North America, especially in the United States. Many biotechnology and pharmaceutical firms involved in the creation and manufacturing of biologics are based in the area. Biologics—such as monoclonal antibodies, vaccinations, and other therapeutic proteins—are in more and greater demand. Biologics frequently offer cutting-edge and successful therapeutic solutions for a range of illnesses, which supports market expansion.


Moreover, the Europe market has been persistently growing over the forecast period. Biopharmaceutical development, encompassing the manufacturing of biologics like antibodies that are monoclonal, vaccines, and other therapeutic proteins, has been increasing throughout Europe. The growing biopharmaceutical industry has increased demand for GMP-compliant manufacturing facilities. Europe has seen an increase in investment in the field of biotech and the life sciences. The invention of biologic pharmaceuticals is receiving funding from public and corporate sectors as well as academic organizations, which has boosted demand for manufacturing facilities that adhere to GMP standards.


Additionally, research and development activities related to biopharmaceuticals have increased significantly in the Asia-Pacific area. The need for GMP-compliant production is being driven by investments made by governments, universities, and private businesses in the creation of innovative biologics for a range of therapeutic applications. In nations like China, South Korea, and India, the biotechnology sector has grown remarkably. The development of biologics by up-and-coming biotech businesses has created a need for GMP-compliant manufacturing facilities to generate batches for clinical and commercial use.


Furthermore, the rest of the world's GMP Biologics market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising investment in research and development sector by both government and private sector. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.


Key Findings of the Study



  • The Asia-Pacific region accounted for the fastest-growing global market due to the increasing investments made by governments, universities, and private businesses in the creation of innovative biologics for a range of therapeutic applications.

  • Creative Diagnostics, Fisher Bioservices(Thermo Fisher Scientific), Polpharma Biologics, Intertek, HemaCare, AGC, AstraZeneca plc, Merck KGaA, Sanofi, GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc.,  Novartis AG, Eli Lilly and Company, Samsung Biologics Co. Ltd., WuXi AppTec.